Pharmaceutical Products
Description
Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsivebreast cancer after surgery
Letrozole has been used for ovarian stimulation by fertility doctors since 2001 because it has fewer side-effects thanclomiphene (Clomid) and less chance of multiple gestation. A Canadian study presented at the American Society of Reproductive Medicine 2005 Conference suggests that letrozole may increase the risk of birth defects.A more detailed ovulation induction follow-up study found that letrozole, compared with a control group of clomiphene, had significantly lower congenital malformations and chromosomal abnormalities at an overall rate of 2.4% (1.2% major malformations) compared with clomiphene 4.8% (3.0% major malformations).Despite this, India banned the usage of letrozole in 2011, citing potential risks to infants. In 2012, an Indian parliamentary committee said that the drug controller office colluded with letrozole& acute;s makers to approve the drug for infertility in India and also stated that letrozole& acute;s use for infertility was illegal worldwide;[5] however, such off-label uses are legal in many countries such as the US and UK.
Read More
Zhuhai Yuansen Bio-Tech Co., Ltd.
pharmaceutical intermediates
Address: Room 508, Huaxing Building110, Yuanlin Road, Jida, Zhuhai, Guangdong, China,
zhuhai, guangdong
China, 519000
Tel: 86-18928065602
Fax: 86-756-8800253
